Results 131 to 140 of about 2,609,117 (176)

Abstract PD9-08: ImPrint immune signature in 10,000 early-stage breast cancer patients from the real-world FLEX database

Cancer Research, 2023
Abstract BACKGROUND: Immune checkpoint inhibitors in combination with chemotherapy have demonstrated an improvement of pathologic complete response (pCR) in patients with HR-HER2- and MammaPrint (MP) High Risk, HR+HER2- tumors in the I-SPY2 TRIAL. However, not all patients benefit from immune checkpoint blockade and these new agents come
Adam M. Brufsky   +26 more
openaire   +2 more sources

Abstract P2-08-06: Defining transcriptomic profiles of breast cancer with early lymph node metastases: A FLEX database sub-study

Cancer Research, 2022
Abstract Introduction: Early lymph node (LN) metastasis often precedes systemic metastasis and corresponds with a 35% decrease in 10-year survival compared to patients without LN metastasis. Understanding biologic pathways involved in early LN metastasis could identify promising drug targets for early-stage breast cancer (EBC) treatment.
Nibash Budhathoki   +11 more
openaire   +2 more sources

Abstract P5-07-05: Deciphering the inferior prognosis of young women with estrogen receptor-positive early-stage breast cancer through full transcriptome analysis: A FLEX database sub-study

Cancer Research, 2022
Abstract Introduction: Young women with estrogen receptor (ER)-positive early-stage breast cancer (EBC) frequently present with larger, higher-grade, more aggressive tumors, with lower ER expression than older women. Post-hoc analyses within the MINDACT and TAILORx cohorts reported that women aged 40-50 with ER+ EBC exhibited a ...
Shubhada Dhage   +12 more
openaire   +2 more sources

Early Termination versus Standard Regimen Duration of Dual Antiplatelet Therapy in Intracranial Aneurysm Patients Treated with Pipeline Embolization Device Flex with Shield Technology: Preliminary Experience of 3 United States Centers.

World Neurosurgery, 2023
BACKGROUND Pipeline Flex Embolization Device with Shield Technology (PED-Shield) is a third-generation flow diverter with reduced thromboembolic potential.
Jaims Lim   +14 more
semanticscholar   +1 more source

First United States Experience Using the Pipeline Flex Embolization Device with Shield Technology for Treatment of Intracranial Aneurysms.

World Neurosurgery, 2021
BACKGROUND The Pipeline Flex Embolization Device with Shield technology (PED-Shield; Medtronic, Dublin, Ireland) is a third-generation flow diverter. Surface modification of the mesh with phosphorylcholine covalently bound to the metal struts aims to ...
J. Cappuzzo   +9 more
semanticscholar   +1 more source

Quadriceps Tendon Versus Hamstring Tendon Autografts for Anterior Cruciate Ligament Reconstruction: A Systematic Review and Meta-analysis

American Journal of Sports Medicine, 2021
Background: Autograft choice in anterior cruciate ligament reconstruction (ACLR) remains controversial, with increasing interest in the usage of quadriceps tendon (QT) autograft versus traditional hamstring tendon (HT) use.
Tze Khiang Tan   +3 more
semanticscholar   +1 more source

Abstract OT2-05-01: FLEX: 30K Full Transcriptome, Real-World Evidence Database for Early-Stage Breast Cancer, and Investigator-Initiated Protocols

Cancer Research, 2023
Abstract FLEX: 30K Full Transcriptome, Real-World Evidence Database for Early-Stage Breast Cancer, and Investigator-Initiated Protocols BACKGROUND: Genomic signatures, such as the 70-gene MammaPrint, provide additional prognostic information for early-stage breast cancer (EBC), such as tumor metastatic potential, and expand the available
Alejandra Perez   +11 more
openaire   +1 more source

Periprocedural complications of second-generation flow diverter treatment using Pipeline Flex for unruptured intracranial aneurysms: a systematic review and meta-analysis

Journal of NeuroInterventional Surgery, 2019
Background Flow diverters are a breakthrough treatment for large and giant intracranial aneurysms but carry a risk of periprocedural death or major stroke.
K. Bhatia   +5 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy